Quadrant Private Wealth Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.04M | Sell |
20,043
-435
| -2% | -$93.6K | 1.13% | 21 |
|
|
2026
Q1 | $4.45M | Buy |
20,478
+1,700
| +9% | +$377K | 0.69% | 37 |
|
|
2025
Q4 | $4.29M | Sell |
18,778
-1,241
| -6% | -$283K | 0.7% | 35 |
|
|
2025
Q3 | $4.64M | Buy |
20,019
+744
| +4% | +$152K | 0.85% | 31 |
|
|
2025
Q2 | $3.58M | Sell |
19,275
-267
| -1% | -$49.6K | 0.74% | 34 |
|
|
2025
Q1 | $4.09M | Sell |
19,542
-589
| -3% | -$115K | 1.02% | 25 |
|
|
2024
Q4 | $3.58M | Sell |
20,131
-29
| -0.1% | -$5.33K | 0.88% | 26 |
|
|
2024
Q3 | $3.98M | Sell |
20,160
-5,238
| -21% | -$978K | 0.99% | 26 |
|
|
2024
Q2 | $4.36M | Buy |
25,398
+93
| +0.4% | +$15.4K | 1% | 24 |
|
|
2024
Q1 | $4.61M | Sell |
25,305
-5,651
| -18% | -$974K | 1.17% | 18 |
|
|
2023
Q4 | $4.8M | Buy |
30,956
+196
| +0.6% | +$28.6K | 1.33% | 15 |
|
|
2023
Q3 | $4.59M | Sell |
30,760
-1,032
| -3% | -$152K | 1.54% | 14 |
|
|
2023
Q2 | $4.28M | Buy |
31,792
+2
| +0% | +$293 | 1.24% | 17 |
|
|
2023
Q1 | $5.07M | Sell |
31,790
-11
| -0% | -$1.68K | 1.58% | 9 |
|
|
2022
Q4 | $5.14M | Buy |
+31,801
| New | +$4.88M | 1.72% | 8 |
|
|
2022
Q2 | $4.76M | Sell |
31,063
-266
| -0.8% | -$40.6K | 1.95% | 8 |
|
|
2022
Q1 | $5.08M | Sell |
31,329
-3,407
| -10% | -$495K | 1.89% | 8 |
|
|
2021
Q4 | $4.7M | Buy |
34,736
+2,544
| +8% | +$301K | 1.75% | 10 |
|
|
2021
Q3 | $3.47M | Buy |
32,192
+345
| +1% | +$39.4K | 1.43% | 16 |
|
|
2021
Q2 | $3.59M | Sell |
31,847
-3,910
| -11% | -$440K | 1.45% | 18 |
|
|
2021
Q1 | $3.87M | Sell |
35,757
-67
| -0.2% | -$7.17K | 1.68% | 13 |
|
|
2020
Q4 | $3.84M | Buy |
35,824
+1,210
| +3% | +$116K | 1.71% | 12 |
|
|
2020
Q3 | $3.03M | Buy |
34,614
+30,025
| +654% | +$2.83M | 1.53% | 14 |
|
|
2020
Q2 | $451K | Buy |
4,589
+882
| +24% | +$77.7K | 0.26% | 91 |
|
|
2020
Q1 | $282K | Buy |
3,707
+483
| +15% | +$41.1K | 0.24% | 102 |
|
|
2019
Q4 | $285K | Buy |
+3,224
| New | +$268K | 0.26% | 85 |
|
|
2019
Q2 | – | Sell |
-2,662
| Closed | -$215K | – | 107 |
|
|
2019
Q1 | $215K | Buy |
2,662
+317
| +14% | +$25.9K | 0.2% | 96 |
|
|
2018
Q4 | $216K | Buy |
2,345
+54
| +2% | +$4.75K | 0.23% | 87 |
|
|
2018
Q3 | $217K | Buy |
2,291
+23
| +1% | +$2.18K | 0.19% | 89 |
|
|
2018
Q2 | $210K | Buy |
2,268
+50
| +2% | +$4.88K | 0.2% | 90 |
|
|
2018
Q1 | $210K | Sell |
2,218
-282
| -11% | -$31K | 0.27% | 80 |
|
|
2017
Q4 | $242K | Buy |
+2,500
| New | +$236K | 0.25% | 78 |
|
Other funds holding ABBV
ECSS
ATO
Quadrant Private Wealth Management's ABBV Position: Q2 2026 in Review
Quadrant Private Wealth Management reduced its AbbVie (ABBV) stake by 2.1% in Q2 2026, selling an estimated $93.6K and leaving 20,043 shares worth $5.04M. The position accounts for 1.13% of the portfolio, ranked #21.
Quadrant Private Wealth Management first reported a position in ABBV in Q4 2017 and has held it in 32 quarters since. The position peaked at $5.14M in Q4 2022. 2,108 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Quadrant Private Wealth Management held 20,043 shares of AbbVie worth $5.04M as of Q2 2026.
- Quadrant Private Wealth Management sold 435 AbbVie shares in Q2 2026, an estimated $93.6K.
- AbbVie made up 1.13% of Quadrant Private Wealth Management's portfolio in Q2 2026, its #21 holding.
- Quadrant Private Wealth Management first reported a position in AbbVie in Q4 2017 and has held it in 32 quarters since.
- Quadrant Private Wealth Management's AbbVie position peaked at $5.14M in Q4 2022.
- 2,108 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Quadrant Private Wealth Management's 13F filing for Q2 2026, filed 30 Jul 2026.